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New Jersey, Newark, New Jersey, USAb; Tufts University School of Medicine, Boston, Massachusetts, USAc; National Institute for Health and Welfare, Turku, Finlandd;
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzaniae; Wadsworth Center, New York State Department of Health, Albany, New York, USAf; and
Boston University School of Public Health, Boston, Massachusetts, USAg
Molecular typing of Mycobacterium tuberculosis can be used to elucidate the epidemiology of tuberculosis, including the rates of
clustering, the frequency of polyclonal disease, and the distribution of genotypic families. We performed IS6110 typing and spo-
ligotyping on M. tuberculosis strains isolated from HIV-infected subjects at baseline or during follow-up in the DarDar Trial in
Tanzania and on selected community isolates. Clustering occurred in 203 (74%) of 275 subjects: 124 (80%) of 155 HIV-infected
subjects with baseline isolates, 56 (69%) of 81 HIV-infected subjects with endpoint isolates, and 23 (59%) of 39 community con-
trols. Overall, 113 (41%) subjects had an isolate representing the East Indian “GD” family. The rate of clustering was similar
among vaccine and placebo recipients and among subjects with or without cellular immune responses to mycobacterial antigens.
Polyclonal disease was detected in 6 (43%) of 14 patients with multiple specimens typed. Most cases of HIV-associated tubercu-
losis among subjects from this study in Dar es Salaam resulted from recently acquired infection. Polyclonal infection was de-
tected and isolates representing the East Indian GD strain family were the most common.
Molecular typing of Mycobacterium tuberculosis isolates hasled to important insights about the epidemiology and
pathophysiology of HIV-associated tuberculosis, which has impli-
cations for prevention strategies (17, 21). One of the most widely
used typing methods is the determination of restriction fragment
length polymorphisms based on the insertion sequence IS61110.
Isolates that are unique on IS6110 typing are presumed to result
from reactivation disease, while patterns that are part of a cluster
(i.e., a group of identical or similar patterns collected in the same
time frame) are more likely to represent recent transmission. Fur-
ther, related IS6110 types can be grouped into families, which have
been correlated with the geographic origin of the isolates (15).
In countries where HIV and tuberculosis are coendemic, tu-
berculosis due to clustered isolates is common (7, 16, 23). In Tan-
zania, a 1995 cross-sectional study found clustering in 37% of 68
HIV-infected patients (33), while another cross-sectional study
found 83% of 88 isolates from patients with unreported HIV sta-
tus in Northern Tanzania had similar IS6110 patterns (10). A re-
cent meta-analysis of seven studies found a trend toward a higher
proportion of clustering in HIV-infected individuals (16). These
data show that new transmission M. tuberculosis is a greater driver
of the expanding epidemic of HIV-associated tuberculosis than
reactivation of latent infection. However, detailed clinical data are
not typically available in cross-sectional typing studies. Further,
only limited data are available on disease due to simultaneous
infection with two or more strains of M. tuberculosis (polyclonal
disease). The potential for polyclonal infection may be greater in
HIV-infected patients who are at risk for concurrent reactivation
and reinfection (5, 29).
M. tuberculosis genotypes, virulence, and drug resistance vary
geographically. Some African countries have high rates of disease
due to the W-Beijing family, which may be more pathogenic than
other strains (23). The most common genotypic families among
147 tuberculosis isolates reported from Tanzania were the Central
Asian (37%), Latin American Mediterranean (22%), and East-
African Indian (17%) families (7).
During the DarDar Vaccine Trial in Tanzania, we collected
isolates of M. tuberculosis from patients with HIV infection, as well
as community controls, and performed IS6110 typing, spoligotyp-
ing, and drug susceptibility testing (30). These data were analyzed
to determine the rates of clustering, the frequency of polyclonal
disease, and the distribution of genotypic families.
MATERIALS AND METHODS
Isolates of M. tuberculosis. The DarDar Vaccine Trial conducted in Dar
es Salaam, Tanzania, from 2001 through 2008 documented the efficacy
of a whole-cell mycobacterial vaccine, M. vaccae, in preventing tuber-
culosis in HIV-infected adults (30). We collected M. tuberculosis iso-
lates from subjects screened for or enrolled in the trial which included
(i) baseline isolates from 2,960 HIV-infected subjects screened and
deemed ineligible for the trial and (ii) endpoint isolates at the time of
a tuberculosis episode from 2,013 HIV-infected subjects enrolled in
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the trial and monitored prospectively for the development of tubercu-
losis. In addition, a nonrepresentative convenience sample of isolates
from community cases of tuberculosis (e.g., treatment failure and re-
treatment cases) was obtained concurrently without identifiers from
the National Tuberculosis and Leprosy Control Programme (NTLP)
reference laboratory.
Three sputum samples were collected at the baseline screening and at
the time of a suspected tuberculosis episode. The first specimen was col-
lected at the time of the study visit and one each on the subsequent 2 days.
Similarly, blood samples were collected at baseline and when a tubercu-
losis diagnosis was suspected; one specimen was collected concurrently
with the first sputum specimen.
Subjects. Eligible subjects for the DarDar Trial were HIV-infected
adults recruited from HIV testing centers in Dar es Salaam with a baseline
CD4 count of 200 cells/l and a BCG scar. Subjects were screened for
active tuberculosis at baseline with three expectorated or induced sputum
samples and a mycobacterial blood culture. Screened subjects with cul-
ture-confirmed tuberculosis disease at baseline (167 subjects contributing
174 isolates) were ineligible to continue in the study. Eligible subjects were
enrolled in the study, randomized 1:1 to receive vaccine or placebo, mon-
itored for a median of 3.3 years, and evaluated with three expectorated
sputum samples and a mycobacterial blood culture when a tuberculosis
disease endpoint was suspected. At the time of enrollment, all subjects had
a tuberculin skin test performed (TST), and those with reactions of 5
mm were treated with isoniazid at 300 mg daily for 6 months (24). Eligible
DarDar subjects who subsequently developed tuberculosis or a CD4
count of 200 cells/l were counseled and referred to a Tanzanian Min-
istry of Health Care and Treatment Center for antiretroviral therapy
(ART).
Clinical data. Detailed clinical and laboratory data were available for
HIV-infected enrolled DarDar subjects who reached a tuberculosis end-
point: baseline CD4 count, HIV viral load, TST status, and history of
tuberculosis (30). Screened subjects with tuberculosis at baseline were
known to be HIV infected, but no other clinical data were available. Nei-
ther HIV status nor clinical data were available for community controls
provided by the NTLP.
Microbiology. Sputum samples were obtained by expectoration or
induction for acid-fast bacilli stain and mycobacterial culture. Standard
techniques were used and included culture on Löwenstein-Jensen me-
dium and an automated mycobacterial blood culture (MB/BacT; bio-
Mérieux, Durham, NC). Putative M. tuberculosis isolates were inoculated
in duplicate into 7H9 liquid medium supplemented with oleic acid, albu-
min, dextrose, and catalase and 15% glycerol, frozen at 70°C and
shipped to the United States, where they were tested for confirmation of
M. tuberculosis complex using a DNA probe (Accuprobe; Gen-Probe, San
Diego, CA) with a documented specificity of 100% (2, 25). For most
patients, a single colony of M. tuberculosis from a single positive sputum or
blood sample was selected for testing. In some instances, a single colony
from a second positive sputum sample was also tested. Isolates that were
not DNA probe positive for M. tuberculosis complex were not included in
the analysis.
IS6110 typing and spoligotyping. IS6110 typing was performed by the
Public Health Research Institute (PHRI) Center in Newark, NJ, and the
hybridization images were analyzed using Bio Image pattern matching
software (Bio Image) (22). Spoligotyping was performed for 148 isolates
by the New York State Department of Health in Albany, NY, and for 11
isolates at the Mycobacterial Reference Laboratory of the National Insti-
tute for Health and Welfare in Turku, Finland, following standard meth-
ods (21).
Cluster analysis. A cluster was defined as two or more M. tuberculosis
isolates that had IS6110 hybridization patterns that were either (i) indis-
tinguishable or (ii) differed by one band and, when available, had a match-
ing spoligotype result. Multiple isolates from the same patient were in-
cluded in the determination of polyclonal disease but removed from all
other analyses. If a patient had two isolates with distinct IS6110 patterns,
they were considered to have polyclonal disease; if at least one IS6110
result met cluster criteria, the patient was classified as clustered. IS6110
results that did not meet cluster criteria were considered unique. Anal-
yses were conducted using Excel and STATA 9 (StataCorp, College
Station, TX).
Molecular analysis and family designation. The PHRI database of
IS6110 typing results comprises more than 27,000 M. tuberculosis isolates
and more than 8,000 different fingerprint patterns (B. Kreisworth, un-
published data). Strain codes were assigned using methods previously
described (3, 22). Strain patterns that are unique in the PHRI database did
not qualify for a strain or family assignment and were given a default
designation (i.e., “001”). The PHRI TB Center archived IS6110 fingerprint
pattern library was mapped to one of nine M. tuberculosis major clusters as
described by Gutacker et al. (15).
DST. Isolates were sent to the Mycobacterial Reference Laboratory
of the National Institute for Health and Welfare in Turku, Finland,
where drug susceptibility testing (DST) was performed. Isolates were
cultured on Löwenstein-Jensen medium, and DST for first-line drugs
was performed on Middlebrook 7H10 agar by the disk-elutriation
method using standardized protocols (32). Resistance to pyrazinamide
was determined according to a method described by Brander (4). DST
for the second-line drugs was performed with the narrow-range MIC
method.
Human subject protection. The study protocol of the DarDar Vac-
cine Trial was approved by the Dartmouth Committee for the Protection
of Human Subjects, by the Muhimbili University of Health and Allied
Sciences Research Ethics Committee, and by the Division of AIDS Clinical
Science Review Committee, National Institutes of Health. Informed con-
sent was obtained from all study participants. The study was conducted in
compliance with good clinical practice guidelines.
Statistical analyses. For two group comparisons, we used a Mann-
Whitney U test, Student t test, and chi-squared test as appropriate. In
all cases, we used a two-tailed threshold for a statistical significance of
P  0.05. Analyses were done with STATA 9 (StataCorp, College Sta-
tion, TX).
RESULTS
Clustering. IS6110 typing was performed on 327 isolates (174
baseline, 109 endpoint, and 44 community isolates) and clustering
determined for 281 isolates (156 baseline, 86 endpoint, and 39
community) from 275 subjects after removal of duplicate, false
positive and uninterpretable results (Fig. 1). Clustering occurred
in 203 (74%) of 275 subjects overall. Among 236 study subjects,
clustering was observed in 180 (76%): in 124 (80%) of 155 subjects
with baseline isolates and in 56 (69%) of 81 subjects with endpoint
isolates (P  0.063). A total of 45 clusters were identified involving
study subjects; the median number of subjects in a cluster was 3,
with a range from 2 to 27 (Table 1). Among the 39 community
controls for whom no clinical data were available (Fig. 1), cluster-
ing was observed in 23 (59%) subjects.
Among subjects with endpoint isolates, 25 (74%) of 34 vac-
cine-recipients belonged to one of 16 clusters and 31 (66%) of 47
placebo-recipients belonged to one of 20 clusters (P  0.47).
Among 20 subjects with disseminated tuberculosis (defined per
protocol by positive blood culture), 14 (60%) were clustered.
There were no significant differences in characteristics of patients
with clustered or unique isolates including the frequency of prior
treatment for tuberculosis or positive TST at baseline (Table 2).
Polyclonal disease. Polyclonal disease was detected in 6 (43%)
of the 14 subjects with multiple isolates available for IS6110 typ-
ing. Of 6 subjects with at least two isolates from sputum, 3 (50%)
had polyclonal disease. Five of these subjects (including two poly-
clonal cases) had both specimens collected over a 2-day period.
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The remaining subject was polyclonal based on isolates collected
5.5 months apart; the patient was successfully treated with 9
months of therapy. Among eight subjects with concurrent sputum
and blood isolates, three (38%) had polyclonal disease and were
previously reported in our study of disseminated tuberculosis
(29).
All three subjects with polyclonal disease in sputum alone had
one clustered isolate. Among the three patients with polyclonal
disease in sputum and blood, one had neither isolate clustered,
one had one isolate clustered and one had both isolates clustered
(Table 3).
Families. Thirty-one different IS6110 families were repre-
sented in the results. The East Indian GD family was the most
common with 94 study subjects and 19 community control pa-
tients (41%) contributing (Fig. 2). Thirty-one (38%) enrolled
subjects and 63 (41%) screened subjects had isolates from the GD
family.
FIG 1 Diagram of M. tuberculosis isolate evaluation. This figure describes the breakdown of subjects and their isolates by category (screened subjects with
baseline isolates, enrolled subjects with endpoint isolates, and community subjects with control isolates) included in the analysis and the degree of clustering and
East Indian GD family representation in each. Baseline isolates were obtained from HIV-infected subjects when screened for the DarDar Vaccine Trial; endpoint
isolates were obtained from enrolled HIV-infected subjects at the time of a tuberculosis diagnosis. Superscripts: a, uninterpretable results were mostly the result
of mixed cultures caused by contamination or representative of a mixed infection; b, twelve duplicate results from nine subjects with multiple specimens were
removed from the main analysis but included in the determination of polyclonal disease; c, includes one polyclonal disease subject with two isolates; d, includes
five polyclonal disease subjects with two isolates each.
TABLE 1 Cluster size frequency and distribution among 236 study
subjectsa











a Includes one study subject with polyclonal disease whose isolates belonged to two
different clusters.
TABLE 2 Characteristics of subjects with endpoint isolates who had








Median age (yrs) 35 32 0.79
No. of male subjects (%) 11 (20) 8 (32) 0.23
Baseline CD4 count (median
cells/l)
348 342 0.79




No. of subjects (%) with prior
treatment for tuberculosis
11 (20) 4 (16) 0.70
Baseline ART (no.) 0 0
TST  5 mm, no. (%)d 33 (60) 19 (76) 0.16
No. of subjects (%) that
received isoniazid
28 (50) 13 (52) 0.87
No. of subjects (%) that
received M. vaccae vaccine
25 (45) 9 (36) 0.47
a ART, antiretroviral therapy; TST, tuberculin skin test.
b P values were determined by using the Mann-Whitney U test, Student t test, and chi-
squared analyses as appropriate.
c n  53.
d n  55 clustered; n  25 unique.
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DST. DST for the first-line drugs was performed on 238 M.
tuberculosis isolates from 233 study subjects. A total of 207 (89%)
of the 233 subjects with DST results had isolates susceptible to all
of the first-line drugs, while any resistance was detected in 26
(11%) isolates. Ten (13%) of the 78 endpoint isolates, and 16
(10%) of the 155 baseline isolates had any resistance detected. A
similar rate of resistance was found among the community con-
trol isolates tested (5 of 37, 14%). Among clustered and unique
isolates from study subjects with DST results, 16 of 178 (9%) and
10 of 56 (18%), respectively, had any resistance detected. Of the
five polyclonal disease patients with more than one specimen
tested, four had matching DST results (both pansensitive strains),
and 1 had divergent results (no resistance detected in one strain
and monoresistance to pyrazinamide found in the second strain
tested). Seven isolates (five baseline and two endpoint, 3% overall)
were multidrug-resistant tuberculosis (MDR-TB) No extensively
drug-resistant isolates were detected.
DISCUSSION
This study of prospectively monitored HIV-infected patients in
Tanzania shows that most cases of tuberculosis are clustered and
are therefore likely to represent recent acquisition. Among those
with known HIV infection, the 76% rate of clustering is higher
than the average 68% found in a meta-analysis of seven studies,
and among the highest reported rates (range, 37 to 79%) (16).
Because our sample size was relatively small, with relatively few
community isolates for comparison, the actual rate of clustering
may even be higher, as has been shown with simulation modeling
(13).





No. of isolates clustered in
polyclonal cases
None One Two
Sputum/sputum 3/6 (50) 0 3 0
Sputum/blood 3/8 (38) 1a 1 1
Total 6/14 (43) 1/6 4/6 1/6
a Clustered isolate was from blood.
FIG 2 M. tuberculosis strains from the study subjects in a phylogenetic framework. This figure depicts the evolutionary phylogenic tree of M. tuberculosis strain
families and the number of isolates from each identified in our study population. RFLP, restriction fragment length polymorphism. A total of 327 isolates were
examined, including 281 RFLP results from 275 subjects (one isolate per subject included in the analysis except for two isolates per subject for six subjects with
polyclonal disease), 204 clustered isolates (from 203 subjects), and 77 nonclustered isolates (from 72 subjects).
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Recurrent tuberculosis is a major problem for individuals liv-
ing in areas of tuberculosis endemicity (14). In our study, the
prevalence of previous tuberculosis disease was similar among
subjects whose isolates were and were not clustered. This suggests
that in HIV-infected patients, previous tuberculosis disease does
not enhance resistance to subsequent reinfection. In both HIV-
infected and HIV-uninfected subjects with a first episode of tuber-
culosis disease, the risk of a second episode is higher than the risk
of a first episode among persons living in the same community
(12). In contrast, among patients without HIV infection and in
animal models, latent tuberculosis infection has been shown to
provide protection against tuberculosis disease upon re-exposure
(1, 8), likely because an immunologic response that contains a
tuberculosis infection also provides resistance to a new exposure.
The high rate of clustering is consistent with numerous studies
that demonstrate most cases of tuberculosis in HIV are due to
reinfection. This finding suggests that in addition to administra-
tion of isoniazid for 6 months to prevent reactivation, other strat-
egies should focus on prevention of reinfection: for example, 36
months of isoniazid and prompt initiation of antiretroviral ther-
apy (19, 26, 30). The DarDar Trial demonstrated vaccine admin-
istration reduced the incidence of definite tuberculosis for up to 4
years. The molecular analysis reported here indicates that the sub-
stantial majority of incident cases involved clustered isolates con-
sistent with recent infection (30). We conclude that in the popu-
lation studied the M. vaccae vaccine prevents new infections. The
observation that the rates of clustering were not different between
the vaccine and control groups may reflect the limitations of the
molecular data set as discussed below.
Polyclonal disease, defined as simultaneous infection with two
or more different M. tuberculosis strains, has been described as
rare in some settings (9) but was found in 17% of new cases and
23% of retreatment cases in South Africa (31). We found poly-
clonal disease in 6 of 14 (43%) of tested subjects, and this rate may
be an underestimate because most subjects had only one colony
from a single specimen typed. In studies of disseminated M. avium
in AIDS we have shown that detection of polyclonal disease in-
creases when multiple colonies are tested from each positive clin-
ical culture (27). Four of the six subjects with polyclonal disease
had one clustered isolate and one unique isolate, raising the pos-
sibility that these subjects had simultaneous reactivation disease
and new infection.
With disseminated M. avium infection in HIV we have ob-
served differential drug susceptibility among patients with poly-
clonal disease and two different isolates (28). Only one of our
subjects with polyclonal disease had different DST results for their
two different strains. In regions where drug-resistant tuberculosis
is more common than in Tanzania, polyclonal infection might
involve one drug-sensitive and one drug-resistant isolate. Studies
are needed of DST results from polyclonal isolates in these re-
gions.
We found that the East Indian GD family of M. tuberculosis
isolates was predominant among tuberculosis patients in Dar es
Salaam, Tanzania. Isolates of the GD strain family are highly prev-
alent in India and Pakistan and among immigrants from this re-
gion. Presence of these genotypes in East Africa is not surprising
given well-documented migration and trade-related travel pat-
terns over several centuries, beginning as early as the 9th century.
However, the predominance we observed contrasts with a previ-
ous study in which the Central Asian family was predominant
among 147 M. tuberculosis isolates from patients in Dar es Salaam
(7); no additional clinical information, including HIV status, was
available regarding these patients. Further, other genotypic fami-
lies predominate in neighboring countries: the European/Ameri-
can lineage in Malawi and the W-Beijing and the CC strain fami-
lies in South Africa (7, 11, 24). In both the South Africa and
Malawi studies, East Indian GD strain families were rare (2% in
South Africa, 9% East African/Indian, and 2% East Asian in Ma-
lawi) (11, 23). Despite its prevalence in South Africa, a W-Beijing
strain was present in only one subject in our study population.
Consistent with other studies in Africa, most strains belong to the
principal genetic groups I and II, the most ancestral strain types.
Most of the isolates evaluated here were drug susceptible, a
finding consistent with the recent national report on tuberculosis
drug resistance in Tanzania (6). In that report, isolates from 8.3%
of new and 20.6% of retreatment patients had resistance to any of
the first-line drugs. MDR-TB rates were very low at 1.1% in new
and 3.9% in retreatment patients. In the present study, MDR-TB
was identified in 3% of clustered isolates. Such results suggest tight
control of tuberculosis drugs and compliance with the NTLP
guidelines has been successful in limiting the emergence of drug-
resistant strains.
The M. tuberculosis isolates studied here were identified
through prospective, active case finding in the context of a phase
III clinical trial (30). Further, baseline mycobacterial cultures were
obtained regardless of baseline symptomatology, suggesting that
our diagnostic work-up for tuberculosis was likely more sensitive
than routine clinical practice in low-income countries.
There are several limitations to our study. Our study popula-
tion was limited to patients with prior BCG vaccination and a CD4
count of 200 cells/l and thus does not represent all patients
with HIV infection. Our isolate sets did not represent all patients
diagnosed with tuberculosis from Dar es Salaam in the given time
frame, and we may have therefore missed identifying some cases as
clustered. Our community isolates were not a representative sam-
ple since mycobacterial culture is not routinely performed on all
patients with suspect tuberculosis but rather reserved for cases in
which drug resistance is being considered (e.g., treatment failure
and retreatment cases). Although enrolled subjects had both
blood and sputum cultures obtained and tested by IS6110 per
protocol, IS6110 testing of duplicated sputum samples from the
same subject was not systematic, and rates of polyclonal infection
in this subgroup may not be representative. Finally, although pro-
cedures were in place to prevent coughing subjects from exposure
to other subjects, study subjects who contributed endpoint iso-
lates for analysis were all seen in the same study outpatient facility,
and we cannot exclude the possibility of nosocomial transmission
of some cases and artificial elevation of apparent clustering rates.
In summary, we have shown that clustered and therefore newly
acquired M. tuberculosis infection, particularly with the East Afri-
can GD family, is the major cause of incident HIV-associated tu-
berculosis disease in Dar es Salaam, Tanzania. Polyclonal disease
was documented, including simultaneous disease with both clus-
tered and nonclustered isolates, suggesting that reactivation and
new infection may occur together.
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